Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Mar 2005

Delaugerre Constance, Roudiere Laurent, Peytavin Gilles, Rouzioux Christine, Viard Jean-Paul, Chaix Marie-Laure

Abstract excerpt

The human immunodeficiency virus type 1 (HIV-1) resistance profile, K65R, K70E and M184V, on reverse transcriptase gene was associated with the virologic rebound consecutively to the switch of lopinavir/r to tenofovir DF in a stable regimen with nucleoside backbone of abacavir, lamivudine and didanosine. The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Didanosine
Share to Dideoxynucleosides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Lopinavir

Share to Organophosphonates

Share to Pyrimidinones

Share to Tenofovir

Source

Identifiers

PMID: 15722030
DOI: 10.1016/j.jcv.2004.05.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.PMID 15722030Read ↗

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.Semantic proximity Read ↗

Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.Semantic proximity Read ↗

Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.Semantic proximity Read ↗

Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.Semantic proximity Read ↗

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.Semantic proximity Read ↗

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.Semantic proximity Read ↗

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Semantic proximity Read ↗

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.Semantic proximity Read ↗

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.Semantic proximity Read ↗

[HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].Semantic proximity Read ↗

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Semantic proximity Read ↗

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.